SAN FRANCISCO — A port delivery system device with ranibizumab was effective, well tolerated and required infrequent refills in patients with neovascular age-related macular degeneration, according to final end-of-study results of the LADDER phase 2 trial.
The study examined the durability, efficacy and safety of the surgically implanted PDS device (Genentech) compared to the gold standard of monthly intravitreal injections of ranibizumab over a mean of 22 months, Carl Regillo, MD, said at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.
A total of 220
Uncategorized